{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"272.190","value":"264.18"},{"groupId":"OG001","spread":"187.866","value":"256.69"}]}],"title":"Baseline (n:198, 195)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"808.316","value":"307.46"},{"groupId":"OG001","spread":"541.933","value":"299.03"}]}],"title":"Cycle 2 Day 1 (n: 185, 184)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"187.329","value":"263.81"},{"groupId":"OG001","spread":"250.841","value":"253.37"}]}],"title":"Cycle 3 Day 1 (n: 185, 174)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"223.980","value":"258.03"},{"groupId":"OG001","spread":"163.561","value":"242.17"}]}],"title":"Cycle 4 Day 1 (n: 171, 159)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"description":"This biomarker is related to angiogenesis pathway, was analyzed to determine the effects of everolimus on plasma antiangiogenic molecules.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 10 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).","id":"OG000","title":"Everolimus 10 mg/Day"},{"description":"Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"The Full Analysis Set (FAS) consists of all patients who were randomized.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1","title":"Plasma Angiogenesis Marker: Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR1)","type":"SECONDARY","unitOfMeasure":"pg/mL"}